YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIL-781 Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM).

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YH12852 is a potent, highly selective 5-HT4 receptor agonist with pKi of 10.3, exhibits more potent agonistic activity (pEC50=11.4) than both tegaserod and prucalopride.

Y-39983 (Y39983) is a potent and selective p160 ROCK inhibitor with Ki of 140 nM.

Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300.

XZH-5 is a small moelcule that inhibits constitutive and interleukin-6-induced STAT3 phosphorylation, inhibits STAT3 DNA binding ability and downregulation of STAT3 downstream genes.

Xylometazoline HCl

Xylazine Hydrochloride is α2 class of adrenergic receptor agonist.

XX-650-23 is a small molecule inhibitor of CREB, blocks CREB/CBP interaction (IC50=3.2 uM) and disrupts CREB-driven gene expression.

XR-5000 (Acridine Carboxamide.

XR 5118 is a small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 3.5 uM, binds to PAI-1 and reduces plasma PAI-1 activity levels, promotes endogenous thrombolysis and inhibits thrombus accretion.

XMU-MP-2 is a potent and selective BRK/PTK6 (breast tumor kinase) inhibitor with biochemical IC50 of 3.2 nM.

XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively.

XL-281 (BMS 908662) is a potent, selective, orally active inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models.

XL188 (XL-188) is a potent, selective, non-covalent active-site inhibitor of USP7 with IC50 of 90 nM and 193 nM for USP7 full length enzyme and catalytic domain, respectively.

XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM.

XF-73 (Exeporfinium chloride) is a novel broad-spectrum antibacterial agent that inhibits a range of gram-positive bacterial species (MIC=0.25-4 mg/mL), including Staphylococcus aureus.

XEN-402 (Funapide.

Xanthyletin is a coumarin isolated from Citrus, with anti-tumor and anti-bacterial activities. Xanthyletin also inhibits symbiotic fungus cultivated by leaf-cutting ants.

Xanomeline(LY246708) is a selective M1 muscarinic receptor agonist.

Xamoterol (ICI 118587) is a third-generation adrenergic β1 adrenergic receptor partial agonist that acts as a cardiac stimulant..

Xamoterol (ICI 118587) is a third-generation adrenergic β1 adrenergic receptor partial agonist that acts as a cardiac stimulant..

WZ-4-49-8 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 67 nM.

WYE-151650 is a novel potent, selective JAK3 inhibitor with IC50 of 0.8 nM, displays 36-, 14-, and 34-fold selectivity against JAK-1, JAK-2, and Tyk-2, respectively.

WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor

WYC-209 is a novel synthetic retinoid that inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with IC50 of 0.19 uM, targets retinoic acid receptor (RAR).

WY-135 (WY135) is a novel potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively.

WX-554 is an oral, small molecule allosteric inhibitor targeting mitogen-activated protein kinase kinase (MEK1 and MEK2) with an estimated IC50 of 4.7 and 10.7 nM, respectively.